Camrelizumab Combo Doubles 5-Year Survival in Phase 3 Lung Cancer Trial
Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a Phase 3 trial.
Read More
Tagrisso May Improve Survival in Advanced EGFR-Mutant NSCLC
Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer.
COCOON Trial Regimen Reduces Dermatologic Side Effects in Mutated Lung Cancer
The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 trial data showed.
First-line Rybrevant Combo Extends Survival in Advanced Lung Cancer
First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.
